Innate Pharma (Innate Pharma) EV-to-EBIT : -24.07 (As of May. 24, 2024)

View and export this data going back to 2015. Start your Free Trial

What is Innate Pharma EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Innate Pharma's Enterprise Value is $182.36 Mil. Innate Pharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-7.58 Mil. Therefore, Innate Pharma's EV-to-EBIT for today is -24.07.

The historical rank and industry rank for Innate Pharma's EV-to-EBIT or its related term are showing as below:

IPHA' s EV-to-EBIT Range Over the Past 10 Years
Min: -860.65 Med: -4.2 Max: 102.89
Current: -23.92

During the past 13 years, the highest EV-to-EBIT of Innate Pharma was 102.89. The lowest was -860.65. And the median was -4.20.

IPHA's EV-to-EBIT is ranked worse than
100% of 421 companies
in the Biotechnology industry
Industry Median: 10.43 vs IPHA: -23.92

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Innate Pharma's Enterprise Value for the quarter that ended in Dec. 2023 was $169.04 Mil. Innate Pharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-7.58 Mil. Innate Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -4.48%.

Innate Pharma EV-to-EBIT Historical Data

The historical data trend for Innate Pharma's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innate Pharma EV-to-EBIT Chart

Innate Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

33.40

-288.73

-6.16

-3.51

-22.98

Innate Pharma Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															-6.16	-	-3.51	-	-22.98

Competitive Comparison of Innate Pharma's EV-to-EBIT

For the Biotechnology subindustry, Innate Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innate Pharma's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innate Pharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Innate Pharma's EV-to-EBIT falls into.

Innate Pharma EV-to-EBIT Calculation

Innate Pharma's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	182.356	/	-7.576
	=	-24.07

Innate Pharma's current Enterprise Value is $182.36 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Innate Pharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-7.58 Mil.

Innate Pharma (NAS:IPHA) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Innate Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-7.576	/	169.0376
	=	-4.48 %

Innate Pharma's Enterprise Value for the quarter that ended in Dec. 2023 was $169.04 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Innate Pharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-7.58 Mil.

Innate Pharma EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Innate Pharma's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Innate Pharma (Innate Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (NAS:IPHA) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

IPHYF:USA 0EVI:UK IPH:France IDDA:Germany

Address

117, Avenue de Luminy, Marseille, FRA, 13009

Website

https://www.innate-pharma.com

Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, avdoralimab, and others.